Handelsavisen
prelaunch
Companies Basic Materials VALN.NS
VA
VALN.NS NSE (India) Specialty Chemicals

Valiant Organics Ltd

$306,20
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-12,9 %
ROE
-2,4 %
Net margin
-9,7 %
Debt / equity
0,35
Beta
52w range
Volume
Day range
$5,23–$5,37
Prev close
$5,23
Open
$5,35
Next earnings
Ex-dividend
TR 1Y
About

Valiant Organics Ltd is a specialty chemicals company that produces and sells chemical products, primarily generating revenue through the sale of these products to industrial and commercial customers.

Business. Valiant Organics Ltd (VALN.NS) is a specialty chemicals company operating within the Basic Materials sector. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorBasic Materials
Business sectorChemicals
IndustrySpecialty Chemicals
ActivityChemicals
Generated · model-assisted
Sell-side consensus
BUY4 analysts
3 buy0 hold1 sell
Avg 12m price target12,72

Analyst recommendations

4 analysts · consensus Buy
Buy3
Hold0
Sell1
12-month price target
12,72
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
4 analysts · indicative
Ownership
Wells Fargo Advisors
largest disclosed fund holder
Profitability
-2,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning VALN.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials · THIS SECTOR+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to VALN.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Valiant Organics Ltd (VALN.NS) is a specialty chemicals company operating within the Basic Materials sector. The firm is headquartered in India and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorBasic Materials
    Business sectorChemicals
    IndustrySpecialty Chemicals
    ActivityChemicals
    AI synthesis
    GENERATED

    Valiant Organics Ltd has a debt-to-equity ratio of 0.35, indicating a relatively conservative capital structure with a moderate level of leverage. The company's liquidity position is assessed as medium, with a current ratio of 1.0, suggesting that it has just enough current assets to cover its current liabilities. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity risk if not managed carefully.

    In terms of profitability, Valiant Organics Ltd reported a net loss of INR 172.19 million and an operating loss of INR 228.06 million in the latest period. The company's return on equity (ROE) is -2.36%, and its return on assets (ROA) is -1.38%, both of which are below the typical thresholds for healthy profitability in the specialty chemicals industry. These figures indicate that the company is currently not generating sufficient returns to cover its cost of capital or to satisfy equity investors.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification could expose the company to higher risks if demand in its primary market or product line declines. There is no information available on the geographic distribution of its revenue, which limits the ability to assess regional exposure.

    Valiant Organics Ltd's growth trajectory is currently constrained by its financial performance. The company reported a net loss and an operating loss in the latest period, which suggests that it is not currently growing profitably. There is no data available on revenue growth or future outlook, making it difficult to assess the company's potential for future expansion or improvement in its financial position.

    The company's risk profile includes a medium liquidity risk, as indicated by its current ratio of 1.0 and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential reported. However, the company's financial performance, including its net loss and negative returns, could impact its ability to maintain or improve its capital structure without issuing additional shares or taking on more debt.

    Recent events related to Valiant Organics Ltd include the latest financial results, which show a net loss and an operating loss. There is no information available on recent filings or transcripts that would provide additional insight into the company's operations or strategic direction. The company's financial performance and capital structure suggest that it may need to take corrective actions to improve its profitability and liquidity position.

    Key takeaways
    • Valiant Organics Ltd has a debt-to-equity ratio of 0.35, indicating a relatively conservative capital structure.
    • The company reported a net loss of INR 172.19 million and an operating loss of INR 228.06 million in the latest period.
    • The company's return on equity (ROE) is -2.36%, and its return on assets (ROA) is -1.38%, both of which are below the typical thresholds for healthy profitability in the specialty chemicals industry.
    • Valiant Organics Ltd's liquidity position is assessed as medium, with a current ratio of 1.0.
    • The company's revenue is concentrated in a single business segment, with no significant geographic diversification reported.
    • The company's risk profile includes a medium liquidity risk and a low dilution risk.
    • **margin_outlook_rationale**: The company's profitability is currently negative, with a net loss and an operating loss reported, indicating a need for improvement in cost management and pricing strategies.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Free cash flow improved by 105.2% year-over-year to INR 15 million, indicating a potential stabilization in cash generation capabilities.

    Long-term debt decreased to INR 2.49 billion in the latest period, reflecting a continued trend of deleveraging from previous years.

    The company maintains a low dilution risk profile, suggesting that existing shareholders' equity is not currently under significant threat of erosion.

    BEAR CASE · 1

    Operating margin of -12.9% places the company in the bottom quartile of the Specialty Chemicals cohort, indicating poor operational efficiency.

    In focus — financials by report

    Annual
    ANNUALFiled 2024-05-24
    FY 2024 · Full-year highlights

    Revenue INR 7.23B, −31,3% YoY; Operating income −100,0% YoY.

    RevenueINR 7.23B−31,3 % YoY
    Operating income-INR 102.0k−100,0 % YoY
    Net income-INR 78.3M−108,9 % YoY
    Free cash flow-INR 465.4M−179,0 % YoY
    EPS
    Operating cash flowINR 838.4M−64,8 % YoY
    Financials
    Income statement
    RevenueINR 7.23B
    Gross profitINR 1.94B
    Operating income-INR 102.0k
    Net income-INR 78.3M
    Margins
    Gross margin26.8%
    Operating margin-0.0%
    Net margin-1.1%
    FCF margin-6.4%
    Balance sheet
    Total assetsINR 12.48B
    Total liabilitiesINR 5.19B
    Total equityINR 7.29B
    Cash & equivalents
    Long-term debtINR 2.57B
    Cash flow
    Operating cash flowINR 838.4M
    CapEx-INR 736.2M
    Free cash flow-INR 465.4M
    SBC
    P&L flow · revenue → net income
    Revenue INR 1.77BOperating costs INR 2.00BNet income INR 172.2M
    Highlights
    • Revenue INR 7.23B, −31,3% YoY
    • Operating income −100,0% YoY
    • Net income −108,9% YoY
    • Free cash flow −179,0% YoY
    • Net margin -1.1%

    Valuation FY

    Market price
    $306,20
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $7.29B
    Net cash
    -$2.54B
    Current ratio
    1.0
    Debt / equity
    0.3
    ROA
    -1.4%
    ROE
    -2.4%
    Cash conversion
    -487.0%
    CapEx / revenue
    -41.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
    Partners1
    Pfizer IncPFE.TOPartner95%Source ↗

    Supply chain

    Vendors → VALN ↔ Partners → Customers · click any node to drill
    VENDORSPARTNERSCUSTOMERSVALNVALNValiant Organics Ltd1 entityPfizer IncPharmaceuticalsCA
    1 mention in 10-K0 from corporate websites0 from news dispatches
    Updated 2026-06-24

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,50
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    4
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-06-25 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$4,90
    Mean$12,72
    Median$14,00
    High$18,00
    Spot$306,20
    −95.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-12,9 %Bottom quartile
    Net Margin-9,7 %Bottom quartile
    ROE-2,4 %Bottom quartile
    Capex / Rev-41,6 %Bottom quartile
    D/E0,35Below median
    Cash Conv-4,87Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Valiant Organics Ltd Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    165.5Kshares short-9.1% vs prior
    6.06days to cover
    81.3%short of daily vol
    1.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    VALN.NSCanonical
    NSE (India) · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    VALNPFE.TOSpecialty Chem
    This companySectorPartners

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-16FILINGPROSPECTUS →
    2026-06-05FILING6-K filing →
    2026-06-01FILING6-K filing →
    2026-05-13FILING6-K filing →
    2026-05-05FILING6-K filing →
    2026-04-30FILING6-K filing →
    2026-03-26FILING6-K filing →
    2026-03-23FILING6-K filing →
    2026-03-18FILING6-K filing →
    2026-03-17FILING20-F filing →
    2026-03-09FILING6-K filing →
    2026-03-02FILING6-K filing →
    2024-05-24 21:39 UTCEARNINGSAnnual results — FY 2024 Revenue INR 7.23B · Net INR -78.3M
    2023-05-19 18:31 UTCEARNINGSAnnual results — FY 2023 Revenue INR 10.52B · Net INR 881.2M
    2022-05-25 20:35 UTCEARNINGSAnnual results — FY 2022 Revenue INR 11.53B · Net INR 1.13B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage